Genomic test predicts PCa outcomes in African-American men
The Decipher genomic classifier is as effective in predicting prostate cancer metastasis and mortality in African-American men as it is in Caucasian men, according to new study findings reported by Stephen Freedland, MD, of Cedars-Sinai Medical Center, Los Angeles.
The Decipher genomic classifier is as effective in predicting prostate cancer metastasis and mortality in African-American men as it is in Caucasian men, according to new study findings reported by Stephen Freedland, MD, of Cedars-Sinai Medical Center, Los Angeles.
The data give clinicians confidence that the test can be used in African-American men, Dr. Freedland said in this Urology Times video interview at the Genitourinary Cancers Symposium in San Francisco. “It’s OK to start using this test in black men tomorrow,” he said.
Dr. Freedland discusses the rationale for the study, its key findings, and clinical implications.
Dr. Freedland disclosed the employment of an immediate family member with Genomic Health, stock/other ownership interests with Armune BioScience, and advisory roles with pharmaceutical and diagnostics companies. Three of the study co-authors are employees of Decipher Biosciences (formerly GenomeDx).
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.
